Skip to main content
. Author manuscript; available in PMC: 2023 Jul 15.
Published in final edited form as: J Immunol. 2022 Jun 27;209(2):368–378. doi: 10.4049/jimmunol.2101172

FIGURE 1.

FIGURE 1.

Myeloid cell-specific LRP5/6 ablation promotes colitis. LRP5/6Flox and LRP5/6LysM mice were treated with 3.0% DSS (36–50 kDa) in their drinking water for 8 days before returning to normal water, and, at day 10, the colons of mice were analyzed for inflammation. (A, B) Change in body weight and colon length of LRP5/6Flox and LRP5/6LysM mice. (C) Myeloperoxidase (MPO) activity in the colon. (D) Representative images of H&E-stained colonic sections from DSS-treated LRP5/6Flox and LRP5/6LysM mice (Scale bars, 100 μm). (E) Histopathological score (inflammation + epithelial damage) of colons was graded following analysis of H&E-stained cross-sections of colons of DSS-treated LRP5/6Flox and LRP5/6LysM mice. (F, G) RNA was extracted from colons of untreated and DSS-treated LRP5/6Flox and LRP5/6LysM mice. The expression of indicated genes was quantified by qPCR. (H) Excised colon samples of untreated and DSS-treated LRP5/6Flox and LRP5/6LysM mice were cultured for 2 days ex vivo, and the indicated cytokine levels in the culture supernatants were quantified by ELISA. Data is representative of two experiments (n = 4–5 mice per experiment). Error bars show mean values ± SEM. ***p<0.001